Company: PRGO
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001585364-25-000056
Chunk: 136

Company: PERRIGO Co plc
Filing Date: 2025-05-07
Form: 10-Q
Item: Part II, Item 1
Chunk 136
---
450 basis points compared to the prior year due to the same factors that drove gross profit.

•$67.5 million decrease in operating expenses due primarily to decreased securities litigation costs, decreased selling and administrative costs of $22.3 million due primarily to Project Energize and a decrease in restructuring costs associated primarily with Project Energize. 

CONSUMER SELF-CARE AMERICAS FINANCIAL RESULTS

 Three Months Ended(in millions, except percentages)March 29, 2025March 30, 2024Net sales$620.7 $644.1 Gross profit$200.1 $153.5 Gross profit %32.2 %23.8 %Operating income$64.0 $15.7 Operating income %10.3 %2.4 %

41

Perrigo Company plc - Item 2CSCA

Net sales decreased $23.4 million, or 3.6%, due primarily to:

•$23.0 million decrease, or 3.6%, due primarily to lower net sales in the Digestive Health category, a prior year benefit in the Women's Health category of $15.0 million from initial retailer stocking of Opill® which launched at the end of the prior year quarter, and $8.7 million from previously disclosed net lost distribution of lower margin products within U.S. Store Brand. These were partially offset by higher net sales in the Nutrition category of $14.5 million, stemming from recovery in the infant formula business, as well as higher net sales in the Upper Respiratory category due primarily to higher incidence levels of cough cold compared to the prior year period and improved supply of key products.

CSCA net sales by product category were as follows:

SalesThree Months Ended(in millions, except percentages)March 29, 2025March 30, 2024$ Change% ChangeUpper Respiratory$137.9 $130.3 $7.6 5.8 %Nutrition104.8 90.6 14.1 15.7 %Digestive Health103.0 122.2 (19.2)(15.7)%Pain and Sleep-Aids76.6 82.6 (6.0)(7.3)%Healthy Lifestyle70.4 71.3 (0.9)(1.3)%Oral Care62.0 64.7 (2.